Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · ABEONA THERAPEUTICS INC. (ABEO)

Abeona Therapeutics acquires APT-1011 for $20 million in stock, with a $30 million private placement

Neutral Impact 4 of 5 m&a

Abeona Therapeutics acquired APT-1011, now called ABO-801, a clinical-stage treatment candidate for eosinophilic esophagitis, from Ellodi Pharmaceuticals in exchange for 4,494,383 common shares valued at $20 million, with no upfront cash. The company also agreed to sell 6,400,000 shares and pre-funded warrants for 1,600,043 shares in a private placement for about $30 million, expected to close November 10, 2026, which will add new shares and dilute existing holders.

Key points

  • Ellodi receives 4,494,383 shares valued at $20 million, based on a 20-day VWAP ending the trading day before the November 6, 2026 closing date, and no upfront cash.
  • Further payments to Ellodi include $30 million upon FDA approval of a New Drug Application, up to $30 million on sales milestones, and tiered royalties in the low to mid teen percentages.
  • Private placement of 6,400,000 shares at $3.75 per share plus pre-funded warrants at $3.7499, with Morgan Stanley as sole placement agent and net proceeds for general corporate purposes including ZEVASKYN.
  • One-third of the upfront shares unlock at each of the 6-, 12- and 18-month anniversaries of closing; resale registration for the private placement shares is due within 15 days after closing.

The filing

CompanyABEONA THERAPEUTICS INC. (ABEO)
Form8-K, current report
Filed with the SECNov 9, 2026, 6:30 AM ET
Accession number0001493152-26-050606

Items reported: 1.01 Material Definitive Agreement2.01 Acquisition or Disposition Completed3.02 Unregistered Equity Sale7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 7:05 AM ET, from this filing only.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.